Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition

This article was originally published in The Pink Sheet Daily

Executive Summary

Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."

You may also be interested in...

Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study

A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.

COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.

Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition

The watchdog group plans to file a petition in the next week calling for the withdrawal of Pfizer's COX-2 inhibitors. Celebrex and Bextra are among 180 currently marketed drugs Public Citizen advises consumers "do not use" on its expanded website.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts